 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||
15 February 1995 | Volume 122 Issue 4 | Pages 254-261
Objective: To determine whether a cytogenetic response after interferon-
Design: Retrospective analysis.
Patients: 274 patients with a diagnosis of Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase who were treated with interferon-
Intervention: Therapy with daily subcutaneous interferon-
Results: Overall, 219 (80%) patients achieved a complete hematologic response and 104 (38%) achieved a major cytogenetic response (<35% Philadelphia chromosome-positive cells). Estimated median survival was 89 months. Several pretreatment factors were associated with failure to achieve a major cytogenetic response and with worse survival. The existing prognostic models were generally predictive of which patients were likely to achieve a major cytogenetic response (P
Conclusion: Achieving a cytogenetic response with interferon-
*For members of the Leukemia Service, see Appendix.
Author and Article Information
From the M.D. Anderson Cancer Center, Houston, Texas.
ARTICLE
Prolonged Survival in Chronic Myelogenous Leukemia after Cytogenetic Response to Interferon-
Therapy
therapy in patients with chronic myelogenous leukemia is independently associated with improved survival. -based programs between 1982 and 1990. given at 5 x 106 U/m2 body surface area (highest dose schedule allowed on studies) or the maximally tolerated lower-dose schedule. 
0.01) and of survival outcomes (P 0.01). Multivariate analysis identified bone marrow basophilia (P < 0.01) and splenomegaly (P < 0.01) as independent poor prognostic factors for survival. Achievement of a major cytogenetic response, entered as a time-dependent variable while accounting for the other independent factors, was associated with improved survival (P < 0.001). Comparison of survival (dated from 12 months into therapy) with cytogenetic response at 12 months showed that a cytogenetic response was associated with longer survival (P < 0.001). therapy in patients with chronic myelogenous leukemia was independently associated with improved survival when tested as a time-dependent variable in a multivariate analysis, and this association was confirmed by landmark analysis at 12 months.
For members of the Leukemia Service, see Appendix.
Requests for Reprints: Hagop Kantarjian, MD, Department of Hematology, Box 61, M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030.
Grant Support: In part by National Cancer Institute grant CA19639. Dr. Kantarjian is a Scholar of the Leukemia Society of America.
This article has been cited by other articles:
|
|
 |
|
  H. Kantarjian, C. Schiffer, D. Jones, and J. Cortes Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods Blood, February 15, 2008; 111(4): 1774 - 1780. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Brave, V. Goodman, E. Kaminskas, A. Farrell, W. Timmer, S. Pope, R. Harapanhalli, H. Saber, D. Morse, J. Bullock, et al. Sprycel for Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate Clin. Cancer Res., January 15, 2008; 14(2): 352 - 359. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Agis, W. R. Sperr, S. Herndlhofer, H. Semper, H. Pirc-Danoewinata, O. A. Haas, C. Mannhalter, H. Esterbauer, K. Geissler, C. Sillaber, et al. Clinical and prognostic significance of histamine monitoring in patients with CML during treatment with imatinib (STI571) Ann. Onc., November 1, 2007; 18(11): 1834 - 1841. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Sinai, R. E. Berg, J. M. Haynie, M. J. Egorin, R. L. Ilaria Jr, and J. Forman Imatinib Mesylate Inhibits Antigen-Specific Memory CD8 T Cell Responses In Vivo J. Immunol., February 15, 2007; 178(4): 2028 - 2037. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Rosti, I. Iacobucci, S. Bassi, F. Castagnetti, M. Amabile, D. Cilloni, A. Poerio, S. Soverini, F. Palandri, G. R. Cambrin, et al. Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party Haematologica, January 1, 2007; 92(1): 101 - 105. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. M. Kantarjian, M. Talpaz, F. Giles, S. O'Brien, and J. Cortes New Insights into the Pathophysiology of Chronic Myeloid Leukemia and Imatinib Resistance Ann Intern Med, December 19, 2006; 145(12): 913 - 923. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Kantarjian, M. Talpaz, S. O'Brien, D. Jones, F. Giles, G. Garcia-Manero, S. Faderl, F. Ravandi, M. B. Rios, J. Shan, et al. Survival benefit with imatinib mesylate versus interferon-{alpha}-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia Blood, September 15, 2006; 108(6): 1835 - 1840. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Roy, J. Guilhot, T. Krahnke, A. Guerci-Bresler, B. J. Druker, R. A. Larson, S. O'Brien, C. So, G. Massimini, and F. Guilhot Survival advantage from imatinib compared with the combination interferon-{alpha} plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials Blood, September 1, 2006; 108(5): 1478 - 1484. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Colovic, V Jurisic, G Jankovic, D Jovanovic, L J Nikolic, and J Dimitrijevic Interferon {alpha} sensitisation induced fatal renal insufficiency in a patient with chronic myeloid leukaemia: case report and review of literature. J. Clin. Pathol., August 1, 2006; 59(8): 879 - 881. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Iacobucci, G. Saglio, G. Rosti, N. Testoni, F. Pane, M. Amabile, A. Poerio, S. Soverini, S. Bassi, D. Cilloni, et al. Achieving a Major Molecular Response at the Time of a Complete Cytogenetic Response (CCgR) Predicts a Better Duration of CCgR in Imatinib-Treated Chronic Myeloid Leukemia Patients. Clin. Cancer Res., May 15, 2006; 12(10): 3037 - 3042. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Ault, H. Kantarjian, S. O'Brien, S. Faderl, M. Beran, M. B. Rios, C. Koller, F. Giles, M. Keating, M. Talpaz, et al. Pregnancy Among Patients With Chronic Myeloid Leukemia Treated With Imatinib J. Clin. Oncol., March 1, 2006; 24(7): 1204 - 1208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Z. Carter, D. H. Mak, W. D. Schober, M. Cabreira-Hansen, M. Beran, T. McQueen, W. Chen, and M. Andreeff Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells Blood, February 15, 2006; 107(4): 1555 - 1563. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Iacobucci, G. Rosti, M. Amabile, A. Poerio, S. Soverini, D. Cilloni, N. Testoni, E. Abruzzese, E. Montefusco, E. Ottaviani, et al. Comparison Between Patients With Philadelphia-Positive Chronic Phase Chronic Myeloid Leukemia Who Obtained a Complete Cytogenetic Response Within 1 Year of Imatinib Therapy and Those Who Achieved Such a Response After 12 Months of Treatment J. Clin. Oncol., January 20, 2006; 24(3): 454 - 459. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Crawley, R. Szydlo, M. Lalancette, A. Bacigalupo, A. Lange, M. Brune, G. Juliusson, A. Nagler, A. Gratwohl, J. Passweg, et al. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT Blood, November 1, 2005; 106(9): 2969 - 2976. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Quintas-Cardama, H. Kantarjian, M. Talpaz, S. O'Brien, G. Garcia-Manero, S. Verstovsek, M. B. Rios, K. Hayes, A. Glassman, B. N. Bekele, et al. Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia Blood, March 15, 2005; 105(6): 2281 - 2286. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Kantarjian, J. E. Cortes, S. O'Brien, R. Luthra, F. Giles, S. Verstovsek, S. Faderl, D. Thomas, G. Garcia-Manero, M. B. Rios, et al. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-{alpha} Blood, October 1, 2004; 104(7): 1979 - 1988. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Thomas, S. O'Brien, J. Cortes, F. J. Giles, S. Faderl, S. Verstovsek, A. Ferrajoli, C. Koller, M. Beran, S. Pierce, et al. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma Blood, September 15, 2004; 104(6): 1624 - 1630. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Thomas, S. Faderl, J. Cortes, S. O'Brien, F. J. Giles, S. M. Kornblau, G. Garcia-Manero, M. J. Keating, M. Andreeff, S. Jeha, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate Blood, June 15, 2004; 103(12): 4396 - 4407. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. C. Kluin-Nelemans, G. Buck, S. le Cessie, S. Richards, H. B. Beverloo, J. H. F. Falkenburg, T. Littlewood, P. Muus, D. Bareford, H. van der Lelie, et al. Randomized comparison of low-dose versus high-dose interferon-alfa in chronic myeloid leukemia: prospective collaboration of 3 joint trials by the MRC and HOVON groups Blood, June 15, 2004; 103(12): 4408 - 4415. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Stone Optimizing Treatment of Chronic Myeloid Leukemia: A Rational Approach Oncologist, June 1, 2004; 9(3): 259 - 270. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kantarjian, M. Talpaz, S. O'Brien, G. Garcia-Manero, S. Verstovsek, F. Giles, M. B. Rios, J. Shan, L. Letvak, D. Thomas, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia Blood, April 15, 2004; 103(8): 2873 - 2878. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kantarjian, S. O'Brien, J. Cortes, F. Giles, J. Shan, M. B. Rios, S. Faderl, S. Verstovsek, G. Garcia-Manero, W. Wierda, et al. Survival Advantage with Imatinib Mesylate Therapy in Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) after IFN-{alpha} Failure and in Late CML-CP, Comparison with Historical Controls Clin. Cancer Res., January 1, 2004; 10(1): 68 - 75. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Cortes, F. Giles, S. O'Brien, D. Thomas, G. Garcia-Manero, M. B. Rios, S. Faderl, S. Verstovsek, A. Ferrajoli, E. J. Freireich, et al. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome--positive chronic myeloid leukemia after failure of interferon-{alpha} Blood, July 1, 2003; 102(1): 83 - 86. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Cortes, M. Talpaz, F. Giles, S. O'Brien, M. B. Rios, J. Shan, G. Garcia-Manero, S. Faderl, D. A. Thomas, W. Wierda, et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy Blood, May 15, 2003; 101(10): 3794 - 3800. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Cortes, M. Albitar, D. Thomas, F. Giles, R. Kurzrock, A. Thibault, W. Rackoff, C. Koller, S. O'Brien, G. Garcia-Manero, et al. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies Blood, March 1, 2003; 101(5): 1692 - 1697. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Goldberg, R. A. Madan, S. D. Rowley, A. L. Pecora, J. W. Hsu, and R. Tantravahi Myelodysplastic subclones in chronic myeloid leukemia: implications for imatinib mesylate therapy Blood, January 15, 2003; 101(2): 781 - 781. [Full Text] [PDF]
|
|
|
|
|
|
H. M. Kantarjian, J. E. Cortes, S. O'Brien, F. Giles, G. Garcia-Manero, S. Faderl, D. Thomas, S. Jeha, M. B. Rios, L. Letvak, et al. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses Blood, January 1, 2003; 101(1): 97 - 100. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Kantarjian, S. O'Brien, J. E. Cortes, S. A. Giralt, M. B. Rios, J. Shan, F. J. Giles, D. A. Thomas, S. Faderl, M. De Lima, et al. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia Blood, August 13, 2002; 100(5): 1590 - 1595. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Kantarjian, M. Talpaz, S. O'Brien, T. L. Smith, F. J. Giles, S. Faderl, D. A. Thomas, G. Garcia-Manero, J.-P. J. Issa, M. Andreeff, et al. Imatinib Mesylate for Philadelphia Chromosome-positive, Chronic-Phase Myeloid Leukemia after Failure of Interferon-{alpha}: Follow-Up Results Clin. Cancer Res., July 1, 2002; 8(7): 2177 - 2187. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Weisdorf, C. Anasetti, J. H. Antin, N. A. Kernan, C. Kollman, D. Snyder, E. Petersdorf, G. Nelson, and P. McGlave Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation Blood, March 15, 2002; 99(6): 1971 - 1977. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Baccarani, G. Rosti, A. de Vivo, F. Bonifazi, D. Russo, G. Martinelli, N. Testoni, M. Amabile, M. Fiacchini, E. Montefusco, et al. A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia Blood, March 1, 2002; 99(5): 1527 - 1535. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. G. Savage and K. H. Antman Imatinib Mesylate -- A New Oral Targeted Therapy N. Engl. J. Med., February 28, 2002; 346(9): 683 - 693. [Full Text] [PDF]
|
|
|
|
|
|
F. X. Mahon, X. Delbrel, P. Cony-Makhoul, C. Faberes, J. M. Boiron, C. Barthe, C. Bilhou-Nabera, A. Pigneux, G. Marit, and J. Reiffers Follow-Up of Complete Cytogenetic Remission in Patients With Chronic Myeloid Leukemia After Cessation of Interferon Alfa J. Clin. Oncol., January 1, 2002; 20(1): 214 - 220. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Lee, J. P. Klein, C. Anasetti, J. H. Antin, F. R. Loberiza, B. J. Bolwell, C. F. LeMaistre, M. R. Litzow, D. Marks, E. K. Waller, et al. The effect of pretransplant interferon therapy on the outcome of unrelated donor hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in first chronic phase Blood, December 1, 2001; 98(12): 3205 - 3211. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Bonifazi, A. de Vivo, G. Rosti, F. Guilhot, J. Guilhot, E. Trabacchi, R. Hehlmann, A. Hochhaus, P. C. A. Shepherd, J. L. Steegmann, et al. Chronic myeloid leukemia and interferon-alpha : a study of complete cytogenetic responders Blood, November 15, 2001; 98(10): 3074 - 3081. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Talpaz, S. O'Brien, E. Rose, S. Gupta, J. Shan, J. Cortes, F. J. Giles, S. Faderl, and H. M. Kantarjian Phase 1 study of polyethylene glycol formulation of interferon {alpha}-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia Blood, September 15, 2001; 98(6): 1708 - 1713. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kalidas, H. Kantarjian, and M. Talpaz Chronic Myelogenous Leukemia JAMA, August 22, 2001; 286(8): 895 - 898. [Full Text] [PDF]
|
|
|
|
|
|
H. M. Kvasnicka, J. Thiele, A. Schmitt-Graeff, V. Diehl, R. Zankovich, N. Niederle, L.-D. Leder, and H. E. Schaefer Bone Marrow Features Improve Prognostic Efficiency in Multivariate Risk Classification of Chronic-Phase Ph1+ Chronic Myelogenous Leukemia: A Multicenter Trial J. Clin. Oncol., June 15, 2001; 19(12): 2994 - 3009. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Barthe, F.-X. Mahon, M.-J. Gharbi, C. Faberes, C. Bilhou-Nabera, A. Hochhaus, J. Reiffers, and G. Marit Expression of interferon-{alpha} (IFN-{alpha}) receptor 2c at diagnosis is associated with cytogenetic response in IFN-{alpha}-treated chronic myeloid leukemia Blood, June 1, 2001; 97(11): 3568 - 3573. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Druker, C. L. Sawyers, R. Capdeville, J. M. Ford, M. Baccarani, and J. M. Goldman Chronic Myelogenous Leukemia Hematology, January 1, 2001; 2001(1): 87 - 112. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. D. Cheson, J. M. Bennett, H. Kantarjian, A. Pinto, C. A. Schiffer, S. D. Nimer, B. Lowenberg, M. Beran, T. M. de Witte, R. M. Stone, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes Blood, December 1, 2000; 96(12): 3671 - 3674. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Kantarjian, M. Talpaz, T. L. Smith, J. Cortes, F. J. Giles, M. B. Rios, S. Mallard, J. Gajewski, A. Murgo, B. Cheson, et al. Homoharringtonine and Low-Dose Cytarabine in the Management of Late Chronic-Phase Chronic Myelogenous Leukemia J. Clin. Oncol., October 20, 2000; 18(20): 3513 - 3521. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Le Gouill, P. Talmant, N. Milpied, A. Daviet, M. Ancelot, P. Moreau, J.-L. Harousseau, R. Bataille, and H. Avet-Loiseau Fluorescence In Situ Hybridization on Peripheral-Blood Specimens Is a Reliable Method to Evaluate Cytogenetic Response in Chronic Myeloid Leukemia J. Clin. Oncol., April 7, 2000; 18(7): 1533 - 1538. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. B. McGlave, X. O. Shu, W. Wen, C. Anasetti, A. Nademanee, R. Champlin, J. H. Antin, N. A. Kernan, R. King, and D. J. Weisdorf Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the National Marrow Donor Program Blood, April 1, 2000; 95(7): 2219 - 2225. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Hensley, B. Peterson, R. T. Silver, R. A. Larson, C. A. Schiffer, and T. P. Szatrowski Risk Factors for Severe Neuropsychiatric Toxicity in Patients Receiving Interferon Alfa-2b and Low-Dose Cytarabine for Chronic Myelogenous Leukemia: Analysis of Cancer and Leukemia Group B 9013 J. Clin. Oncol., March 13, 2000; 18(6): 1301 - 1308. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Rodriguez, J. Cortes, M. Talpaz, S. O’Brien, T. L. Smith, M. B. Rios, and H. Kantarjian Serum {beta}-2 Microglobulin Levels Are a Significant Prognostic Factor in Philadelphia Chromosome-positive Chronic Myelogenous Leukemia Clin. Cancer Res., January 1, 2000; 6(1): 147 - 152. [Abstract] [Full Text]
|
|
|
|
|
|
A. Hochhaus, A. Reiter, S. S.{b.}e. A. Reichert, M. Emig, J. Kaeda, B. Schultheis, U. Berger, P. C. A. Shepherd, N. C. Allan, R. Hehlmann, et al. Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission Blood, January 1, 2000; 95(1): 62 - 66. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Kantarjian, M. Talpaz, S. O'Brien, T. Manshouri, J. Cortes, F. Giles, M. B. Rios, C. M. Croce, and M. Albitar Significance of FHIT Expression in Chronic Myelogenous Leukemia Clin. Cancer Res., December 1, 1999; 5(12): 4059 - 4064. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Pane, I. Mostarda, C. Selleri, R. Salzano, A. M. Raiola, L. Luciano, G. Saglio, B. Rotoli, and F. Salvatore BCR/ABL mRNA and the P210BCR/ABL Protein Are Downmodulated by Interferon-alpha in Chronic Myeloid Leukemia Patients Blood, October 1, 1999; 94(7): 2200 - 2207. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. T. Silver, S. H. Woolf, R. Hehlmann, F. R. Appelbaum, J. Anderson, C. Bennett, J. M. Goldman, F. Guilhot, H. M. Kantarjian, A. E. Lichtin, et al. An Evidence-Based Analysis of the Effect of Busulfan, Hydroxyurea, Interferon, and Allogeneic Bone Marrow Transplantation in Treating the Chronic Phase of Chronic Myeloid Leukemia: Developed for the American Society of Hematology Blood, September 1, 1999; 94(5): 1517 - 1536. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Stagno, P. Guglielmo, U. Consoli, P. Fiumara, M. Russo, and R. Giustolisi Successful Healing of Hydroxyurea-Related Leg Ulcers With Topical Granulocyte-Macrophage Colony-Stimulating Factor Blood, August 15, 1999; 94(4): 1479 - 1480. [Full Text] [PDF]
|
|
|
|
|
|
S. Faderl, M. Talpaz, Z. Estrov, and H. M. Kantarjian Chronic Myelogenous Leukemia: Biology and Therapy Ann Intern Med, August 3, 1999; 131(3): 207 - 219. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. O'Brien, H. Kantarjian, C. Koller, E. Feldman, M. Beran, M. Andreeff, S. Giralt, B. Cheson, M. Keating, E. Freireich, et al. Sequential Homoharringtonine and Interferon-alpha in the Treatment of Early Chronic Phase Chronic Myelogenous Leukemia Blood, June 15, 1999; 93(12): 4149 - 4153. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Monitoring Treatment and Survival in Chronic Myeloid Leukemia J. Clin. Oncol., June 1, 1999; 17(6): 1858 - 1858. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Faderl, M. Talpaz, H. M. Kantarjian, and Z. Estrov Should Polymerase Chain Reaction Analysis to Detect Minimal Residual Disease in Patients With Chronic Myelogenous Leukemia Be Used in Clinical Decision Making? Blood, May 1, 1999; 93(9): 2755 - 2759. [Full Text] [PDF]
|
|
Article
